Health

India Formulations business up 23% Net Profit Rs 169 crores

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2021.

Financial Highlights

  • Net Sales for the quarter at Rs 1292 crores.
  • Net Profit for the quarter at Rs 169 crores.
  • Net sales for H-1 FY21 at Rs 2618 crores.
  • Net profit for H-1 FY21 at Rs 334 crores.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said “India Branded Formulation business has posted a strong growth rate for the second consecutive quarter. This is attributed to the consistent efforts to redefine our business strategy and customer relationships, leading to a strong operational performance, along with a market outperforming growth across all our key product segments and therapy areas.”

Operational Highlights

International Business

  • US Generics at Rs 348 crores in the quarter and at Rs 716 Crores for H-1.
  • Ex-US International Formulations at Rs 197 Crores in the quarter and at Rs 394 Crores for H-1.
  • 5 ANDA approvals received during the quarter; 150 Cumulative ANDA approvals.
  • 3 ANDA filings during the quarter; Cumulative ANDA filings at 214.

India Formulations Business

  • India Formulations Business at Rs 509 crores in the quarter and at Rs 989 crores in the H-1.
  • Acute & specialty segment grew faster than represented pharma market.

 API Business

  • API business at Rs 239 crores in the quarter and at Rs 519 crores for H-1.
  • 3 DMF were filed in the quarter.

Summary of Total Revenue is as under:

                                        (Rs in Crores)

Particulars Q2 FY22 Q2 FY21 % Change H-1 FY22 H-1 FY21 % Change
Formulation
  USA

Ex- US

348

197

582

197

(40%)

0%

716

394

1177

373

(39%)

6%

  India 509 415 23% 989 721 37%
API 239 263 (9%) 519 528 (2%)
Total 1292 1457 (11%) 2618 2798 (6%)

 

Summary of Profit is as under:                                                              (Rs in Crores)

Particulars Q2 FY22 Q2 FY21 % Change H1 FY22 H1 FY21 % Change
EBITDA Pre R&D 420 628 (33%) 827 1177 (30%)
EBITDA Pre R&D % 33% 43%   32% 42%  
EBITDA Post R&D 268 455 (41%) 522 871 (40%)
EBITDA Post R&D % 21% 31%   20% 31%  
Profit Before Tax 209 406 (49%) 408 775 (47%)
Net Profit after Tax 169 333 (49%) 334 635 (47%)

 

Shivam
Shivam is one of those gen X kids who wish the world was different. Shivam enjoys surfing the internet without any motive. He reads a lot and loves working on unique projects.
http://dailybiz.news

Leave a Reply

Your email address will not be published.